Oncology Daiichi Sankyo gears up for five ADC launches in 2026 On the sidelines of JPM, Daiichi-Sankyo US CEO Ken Keller told pharmaphorum about the company's big year and its long-term strategy in ADCs.
Oncology ESMO 2025 in review: A new era in oncology, from AI to next-... ESMO 2025 reflected a field in the midst of rapid evolution – one that is increasingly defined by personalisation and data-driven decision-making.
Oncology 5 clinical advances and related implications from ESMO 2025 5 particularly insightful takeaways from this year’s ESMO Congress that merit deeper reflection on where cancer care can go.
Oncology Advances in breast cancer: What’s new from ESMO 2025 ESMO 2025 showcased the breadth and urgency of breast cancer research, which remains one of the most diagnosed malignancies worldwide.
Oncology ESMO 2025 commences: ADCs, AI, and Asia ESMO 2025 has kicked off, with an opening press conference focused on early setting ADCs, the potential of AI in oncology, and new drugs from Asia.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.